Translation and Validation of the Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia (ASTA) to the Brazilian Context: An Instrument Focusing on Arrhythmia Symptoms

Priscila M. S. Cannavan,1 Fernando P. S. Cannavan,2 Ulla Walfridsson,3 and Maria H. B. M. Lopes1

1School of Nursing, University of Campinas, Campinas 13083-970, Brazil
2Department of Cardiology, Clinical Hospital, University of Campinas, Campinas 13083-970, Brazil
3Department of Cardiology, University Hospital, Sweden and Department of Medical and Health Sciences, Linköping University, Linköping, 58185, Sweden

Correspondence should be addressed to Priscila M. S. Cannavan; pmsperling@gmail.com

Received 5 February 2020; Accepted 26 March 2020; Published 10 April 2020

Academic Editor: Francesco Fedele

Copyright © 2020 Priscila M. S. Cannavan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction. The wide variety of symptoms in patients with cardiac arrhythmias can affect daily living activities. The evaluation of symptoms with patient-reported outcome measures (PROMs), with validated instruments, can provide information that contributes to clinical decisions and treatment. In Brazil, however, there is no available scale that evaluates symptoms in different types of arrhythmias. Purpose. This study aimed to translate the Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia symptom scale (ASTA-symptom scale) and then validate the questionnaire in terms of Brazilian culture. Method. The methodological process of cultural adaptation used was based on international literature guidelines consisting of forward translation, synthesis, back translation, review by an expert committee, and pretest. Psychometric analyses were conducted with 140 patients. These included measuring internal consistency (Cronbach’s α), construct validity with item-total correlations, and convergent construct validity with correlations with the quality of life questionnaire for patients with atrial fibrillation-version 2 (QVFA-v2). Usability and understandability were evaluated through the usability evaluation of instruments. Results. The translation and adaptation processes were performed by obtaining the Brazilian Portuguese version of the original Swedish instrument. This version presented the internal consistency of items, evaluated through Cronbach’s α (0.79). Construct validity was demonstrated by item-total correlations for the nine items, all except one reached the level of >0.30 (0.24). Convergent validity showed a high correlation with QVFA-v2 (0.89). As for the evaluation of usability and understanding, after two small suggested changes, no additional alterations were necessary. Conclusion. The psychometric properties of the Brazilian version of ASTA-symptom scale evaluated in this study were satisfactory, and the scale was proved to be a valid and reliable tool to assess the symptom burden in patients with different forms of tachyarrhythmia. The ASTA-Br-symptom scale questionnaire can be an important addition to PROMs for patients with arrhythmias and could help healthcare professionals in decision-making.

1. Introduction

There are several forms of tachyarrhythmia. The classification depends on both characteristics and mechanisms, and they can occur in persons with or without severe heart disease, depending on their characteristics and the mechanism of formation and propagation. Tachyarrhythmia may also occur in individuals with an anatomically normal heart, as well as in those with severe heart disease. Ventricular premature beats and atrial fibrillation (AF) are the most
common arrhythmias, the latter occurring in 3% of the general population, with increasing prevalence in elderly patients [1–5].

The most common symptoms in patients with tachyarrhythmia are palpitations, dyspnoea, dizziness, and chest pain. Symptoms such as anxiety and depression, which are less specific, are also mentioned [5–10].

Regardless of the type of arrhythmia, the manifestations presented by the patients can be both physically and mentally related. This can compromise the performance of normal daily life activities and can have a significant negative impact on quality of life (QoL) [5–9, 11, 12].

The assessment of symptoms with disease-specific patient-reported outcome measures (PROMs) can be a valuable aid when making therapeutic decisions [13]. Therefore, in order to properly evaluate the symptoms, a reliable and valid instrument is required. Most of the instruments aimed at PROMs in patients with arrhythmias which are limited to individuals with AF [14–19]. The Arrhythmia-Specific Questionnaire in Tachycardia and Arrhythmia (ASTA) was developed and validated by a Swedish group and was the first disease-specific questionnaire evaluating both symptoms and health-related quality of life (HRQOL) in patients with different arrhythmia diagnoses. It is divided into two specific scales, the ASTA-symptom scale and the ASTA-HRQOL scale, which can be applied together or separately when evaluating the patient with arrhythmia. It also assesses the different forms of tachyarrhythmia, which make it possible to compare patients with supraventricular and ventricular arrhythmias [20, 21]. The internal consistency of the ASTA-symptom scale was evaluated using Cronbach’s alpha coefficient, construct validity with item-total correlations and convergent and discriminant validity, and concurrent validity was evaluated. Satisfactory results were obtained for all the items [20]. The ASTA questionnaire has been translated into Spanish and Polish and validated in their respective languages [22, 23].

Due to the variety of symptoms and the effects they may have in patients with tachyarrhythmia, this need to be adequately evaluated, but there is no reliable and valid instrument in Brazil for evaluating symptoms. The reliability and validity of the ASTA-symptom scale have been evaluated in other languages, so this scale can also be used in Brazil. However, due to cultural differences between the countries that validated this instrument and Brazil, a translation, adaptation, and validation process is required. Thus, the purpose of this study was to translate, adapt, and evaluate the psychometric properties of the ASTA-symptom scale to the Brazilian culture and also to evaluate its usability and understandability in patients with different forms of tachyarrhythmia.

2. Methods

2.1. Study Design and Data Collection. This was a methodological study [24], with the purpose of translating, adapting, and validating the ASTA-symptom scale. Data were collected at the arrhythmology clinic of a public university hospital and at a private clinic specialising in the care of patients with cardiac arrhythmias, both located in the interior of the State of São Paulo.

2.2. Ethical Aspects. The use of the ASTA-symptom scale was previously authorised by the author of the questionnaire, and the research was approved by the Research Ethics Committee of the University of Campinas (Unicamp) (CAAE: 78539617.7.0000.5404). All participants that agreed to participate signed the informed consent form.

Patients were invited and advised of their voluntary participation in the research and informed that if they withdrew their consent, this would not have any negative effect on their treatment.

2.3. Translation and Adaptation Procedure of the ASTA-Symptom Scale. The ASTA-symptom scale is an instrument developed in Sweden, with nine items evaluating specific symptoms in patients with different types of cardiac arrhythmias. Scores vary from 0 to 27 on a four-point response scale with Likert-type response alternatives ranging from 0 (No) to 3 (Yes, a lot). The scores can be recalculated from 0 to 100, where lower scores characterise fewer symptoms related to arrhythmias [20].

The guidelines for the translation and cultural adaptation of the self-report measures, as recommended by Beaton et al. [25], were used in this study. After the author’s formal authorisation, the translation process was performed.

The original translation was carried out by two independent translators, born in Brazil, whose native language was Brazilian Portuguese, who were fluent in Swedish, and who were currently living in Sweden. Translator 1 (T1) was aware of the objectives of the study, while translator 2 (T2) was not. For the synthesis of the translations (T1 and T2), the versions were shown to the researcher and a mediator, specialist in arrhythmia. The discrepancies between T1 and T2 were analysed and synthesised into a single version of the questionnaire (T12).

The translation of the ASTA-symptom scale back into the original language was carried out by two independent Swedish translators with knowledge of both Brazilian Portuguese language and culture. At this stage, the translators were not aware of the purpose of the study. The synthesis of the version in Portuguese (T12) was made available for the backward translation, which was then translated into the original Swedish language. This translation was the origin of versions BT1 and BT2.

All the previously produced instruments (T1, T2, T12, BT1, and BT2) were reviewed and analysed by a committee of experts that evaluated the equivalences: 1. semantics—maintenance of the meaning of each item after translation into Brazilian Portuguese; 2. idiomatic—adequate translation of colloquial expressions from Swedish to Portuguese; 3. culture—consistency between the terms used in the original version and the corresponding one in Brazilian Portuguese; and 4. conceptual—equivalence between the different conceptual meanings of different cultures, with maintenance of the coherence between the item and the domain to be evaluated. The judges were asked to evaluate
whether the situations evoked or portrayed in the items actually assessed the symptom burden.

The committee was composed of eight members: four translators fluent in both languages, a Brazilian nurse with clinical experience in the area of cardiology in Sweden, a methodologist (a nurse practitioner with knowledge of the theoretical framework), a linguist with knowledge of the Portuguese language, and a physician specialist in cardiac arrhythmias from the Brazilian Society of Cardiac Arrhythmias.

The individual assessment of semantic, idiomatic, cultural, and conceptual equivalence by each member of the committee was performed in two steps: (1) judges scored each item on a Likert scale, with a score of 1 to 4, where 1 indicated no equivalence; 2, it was impossible to evaluate the equivalence without the item being revised; 3 equivalent, but needed minor changes; and 4 completely equivalent. In the same worksheet, the judges still had to evaluate the comprehensiveness and relevance of the questionnaire. All the judges were previously advised on how they should proceed in the evaluation. In this first stage, the content validity index, which measures the agreement between the evaluators, was considered acceptable when equal to or greater than 80% for each item of the instrument [26]. (2) After the first analysis, if necessary, the translated questionnaire was modified, according to suggestions submitted by the judges, ideally aiming to achieve 100% agreement by consensus [26]. At the end, the preliminary version of the questionnaire to be used in the pretest was obtained.

For the pretest, 30–40 participants who met the inclusion criteria and also agreed to participate in the study were interviewed. All participants were informed about the purpose of the study, and the usability and understandability of the translated instrument were assessed using the usability evaluation of instruments [27].

2.4. Validity and Reliability of the Brazilian Portuguese Version of the ASTA-Symptom Scale

2.4.1. Patient Selection. A nonprobabilistic convenience sample of patients with a tachyarrhythmia diagnosis was selected. The sample size would be equivalent to a minimum of 10 respondents for each item of the instrument (ASTA-symptom scale) following literature recommendations [28].

The inclusion criteria were people aged 18 or more, diagnosed with tachyarrhythmia for more than three months, without an implantable electronic cardiac device, score equal to or greater than 5 on the Short Portable Mental Status Questionnaire (SPMSQ) [29], and who agreed to participate in the study after being informed of its purpose.

2.4.2. Study Protocol. Before the medical consultation, the researcher initiated contact and explained the research project. Interviews and data collection took place in a private room. The data were collected by the researcher through a tablet. Each question and related options were read to the patients so that they could indicate their answers. The following instruments were used: the sample characterisation record (developed for this study), the Brazilian Portuguese version of the ASTA-symptom scale, and the quality of life questionnaire for patients with atrial fibrillation-version 2 (QVFA-v2) [18].

The internal consistency analysis of the instruments was performed using software SAS 9.4 and SPSS 22.

2.4.3. Data Analyses. Means, standard deviations, and frequencies were used to describe patient characteristics and symptoms. The Brazilian Portuguese version of the ASTA-symptom scale (ASTA-Br-symptom scale) was psychometrically evaluated regarding data quality, construct validity, and internal consistency reliability.

The convergent validity of the ASTA-Br-symptom scale with the QVFA-v2 questionnaire was evaluated using Spearman’s correlation coefficient [31]. Cohen [32] suggests the following classification of the correlation coefficient: 0.1 to 0.29 (weak), 0.30 to 0.49 (moderate), and greater than or equal to 0.50 (strong).

The hypothesis tested was that there was a correlation between ASTA-Br-symptom and the following domains of the QVFA-v2: palpitations, dyspnoea, chest pain, dizziness, and fatigue.

The internal consistency analysis of the instruments was evaluated using Cronbach’s alpha coefficient, where a coefficient ≥0.70 was considered sufficient. Construct validity was supported by item-total correlations above the acceptable level ≥0.30. [33, 34]. The analyses were performed using software SAS 9.4 and SPSS 22.

3. Results

3.1. Cultural Adaptation. There were no recommendations from the expert committee regarding modifications for clarification/explanation. In order to facilitate usability, the layouts for some questions were redesigned.

For the pretest, the ASTA-Br-symptom scale was applied to a sample of 32 participants with tachyarrhythmia. Along with the ASTA-Br-symptom scale, the Usability Assessment Questionnaire [27] was answered by the participants in order to evaluate the usability of the ASTA-Br-symptom scale, that is, the understanding of instructions and requests and how to answer them. The majority (93.8%) of the respondents reported that the items were easy to understand.
3.2. Patient Demographics. Data were collected between May and October, 2018. For psychometric evaluation, 140 patients with a diagnosis of cardiac arrhythmias were included, with a mean age of 57.2 years (SD 13.1), 55% (n = 77) female, 62.14% (n = 87) studied until elementary school, 79.28% (n = 111) had remuneration of 1 to 2 minimum wages, and only 32.14% (n = 45) were employed. Of these, 135 (96.4%) participants came from the outpatient clinic of the public service.

Regarding clinical characteristics, 129 (92.1%) participants had a diagnosis of supraventricular tachyarrhythmia and 11 (7.9%) had ventricular arrhythmias, with a mean diagnostic time of 106.5 months (SD 112.1), a minimum of three months and a maximum of 42 years, and 118 (84.3%) were not aware of the type of arrhythmia. Participants with associated cardiovascular disease (62.14%) had a mean left ventricular ejection fraction (LVEF) of 60% (SD 10.7) obtained from the echocardiographic data in the medical record. Table 1 presents the clinical characteristics of the participants.

| Variables                                      | N  | %   | LVEF       |
|------------------------------------------------|----|-----|------------|
| Type of cardiac arrhythmia                     |    |     |            |
| Atrial fibrillation                            | 71 | 50.71 |
| Atrial flutter                                 | 19 | 13.57 |
| Atrial tachycardia                             | 2  | 1.43 |
| Paroxysmal supraventricular tachycardia        | 7  | 5.00 |
| Wolff–Parkinson–White                           | 14 | 10.00|
| AV nodal re-entry                              | 16 | 11.43|
| Ventricular tachycardia                        | 1  | 0.71 |
| Ventricular extrasystoles                       | 6  | 4.29 |
| Nonsustained ventricular tachycardia            | 4  | 2.86 |
| Treatment*                                      |    |     |            |
| Medication                                     | 132| 94.29|
| Catheter ablation                              | 17 | 12.14|
| DC electrical cardioversion                    | 5  | 3.57 |
| Hospitalisation                                | 78 | 55.71|
| Associated cardiovascular disease               | 87 | 62.14|
| Antiarrhythmic medication                      | 122| 87.14|
| Class I                                        | 10 | 7.14 |
| Class I                                        | 91 | 65.00|
| Class III                                      | 18 | 12.86|
| Class IV                                       | 3  | 2.14 |
| Oral anticoagulant                             | 77 | 55.00|
| NYHA functional class                          |    |     |            |
| I                                              | 96 | 68.57|
| II                                             | 43 | 30.71|
| III                                            | 1  | 0.71 |
| Cardiovascular diseases*                        |    |     |            |
| Hypertension                                   | 69 | 49.29|
| Cardiac valve replacement                      | 16 | 11.43|
| Dyslipidaemia                                  | 16 | 11.43|
| Chagas disease                                 | 10 | 7.14 |
| Dilated cardiomyopathy                         | 2  | 1.43 |
| Diabetes mellitus                              | 32 | 22.86|
| Other clinical characteristics and comorbidity* |    |     |            |
| Hypothyroidism                                 | 18 | 12.86|
| Systemic lupus erythematosus                   | 3  | 2.14 |

LVEF = left ventricular ejection fraction. *Participants could choose more than one answer option.

As to the onset of symptoms, 62 (44.3%) patients reported that the symptoms started during physical effort and 25 (17.9%) either in situations of stress or emotion; 78 (55.7%) had come close to fainting in connection with arrhythmia, and 35 (25%) had fainted in connection with arrhythmia; 107 (76.4) reported that the symptoms lasted on average less than one hour; and 43 (30.7%) reported having symptoms every day.

Regarding the specificity of the palpitations, the patients were asked and could choose more than one alternative, and 122 (87.1%) reported a feeling that the heart was beating fast, 101 (72.1%) felt the heart beating harder than usual, 57 (40.7%) felt the heart beating irregularly, and 33 (23.6%) reported a feeling that the heart missed one or more beats.

3.3. Internal Consistency Reliability. As in the original version [20], the internal consistency of the Brazilian version presented results with sufficient homogeneity, Cronbach’s alpha = 0.79. All nine items demonstrated satisfactory
internal consistency, with Cronbach’s alpha values ranging from 0.75 to 0.80 if the item was deleted (Table 2).

3.3.1. Construct Validity. The item-total correlations for the nine items in the ASTA-Br-symptom scale reached the level of $>0.30$, ranging from 0.41 (cold sweat) to 0.61 (weakness/fatigue), all except for worry/anxiety, 0.24 (Table 2).

3.3.2. Convergent Construct Validity. The correlation between “ASTA-Br-symptom” scores and “QVFA-v2” questionnaire evaluated by the Spearman correlation coefficient was 0.89 ($p < 0.0001$), showing a strong positive and significant correlation.

4. Discussion

The translated and adapted ASTA-Br-symptom scale demonstrated generally good reliability and validity properties. The study was conducted using a rigorous methodology, with a sample that included participants of both sexes, with atrial and ventricular arrhythmias and with a sample size adequate for the psychometric tests used. The ASTA-symptom scale proposes to evaluate the number of symptoms in patients with different forms of tachyarrhythmia. A thorough review of the literature showed that the ASTA questionnaire is the first one specifically developed to evaluate symptoms in patients with different arrhythmias, making comparisons easy between the different diagnoses. It was also found that this is the only study that reports the use of validated scales in Brazil to assess symptoms in this population.

The adaptation of an existing scale is considered more appropriate than developing new ones for the same construct, and there are significant advantages since the researcher can compare data obtained in different scenarios [35].

The use of disease-specific questionnaires is increasingly frequent since it subsidises health decision-making. However, for their wider use, it is necessary to adapt them for different cultures. For this to be possible, the process of cultural adaptation must take place with methodological rigour to maintain the validity and reliability of the questionnaires [36].

Reliability refers to the degree to which an instrument produces consistent results from its scores. When one item is eliminated and Cronbach’s alpha coefficient increases, this item is not highly correlated with the others and could be eliminated from the instrument, but if the coefficient decreases, it means that the item is highly correlated with the others [37]. The internal consistency value by Cronbach’s alpha was equal to the value obtained in the original instrument. In this study, the item worry/anxiety was borderline and increased Cronbach’s alpha coefficient if deleted [20].

Construct validity was supported by the item-total correlations above the acceptable level ($>0.30$) for all except one of the items, worry/anxiety. However, this did not lead to a withdrawal from the ASTA-Br-symptom scale.

Regarding construct validity, there was a strong correlation between the ASTA-Br-symptom scale and QFVA-v2 questionnaire, supporting convergent validity.

In the sample, there were no patients with a significant reduction in LVEF, showing that the symptoms eventually referred to as breathlessness, weakness/fatigue, and tiredness

| Items                          | Item-total correlation | Symptom scale | Mean (SD) | No, n (%) | Yes, to a certain extent n (%) | Yes, quite a lot n (%) | Yes, a lot n (%) |
|-------------------------------|------------------------|---------------|-----------|-----------|-------------------------------|------------------------|-----------------|
| Symptoms                      | Item-total              | Cronbach if item was deleted |           |           |                               |                        |                 |
|                               | correlation             |               |           |           |                               |                        |                 |
| Breathing during activity      | 0.42                   | 0.78          | 1.54 (1.14)| 39 (27.86)| 21 (15.00)                    | 46 (32.86)             | 34 (24.29)      |
| Breathing even at rest         | 0.51                   | 0.77          | 0.99 (1.10)| 64 (45.71)| 33 (24.57)                    | 23 (16.43)             | 20 (14.29)      |
| Dizziness                      | 0.45                   | 0.78          | 0.96 (1.04)| 63 (45.00)| 34 (24.29)                    | 28 (20.00)             | 15 (10.71)      |
| Cold sweat                     | 0.41                   | 0.78          | 0.91 (1.17)| 76 (54.29)| 25 (17.86)                    | 14 (10.00)             | 25 (17.86)      |
| Weakness/fatigue               | 0.61                   | 0.75          | 1.12 (1.18)| 62 (44.29)| 27 (19.29)                    | 23 (16.43)             | 28 (20.00)      |
| Tiredness                      | 0.58                   | 0.76          | 1.44 (1.21)| 46 (32.86)| 25 (17.86)                    | 30 (21.43)             | 39 (27.86)      |
| Chest pain                     | 0.55                   | 0.76          | 0.93 (1.20)| 78 (55.71)| 21 (15.00)                    | 14 (10.00)             | 27 (19.29)      |
| Pressure/discomfort in the chest | 0.56               | 0.76          | 1.07 (1.15)| 62 (44.29)| 31 (22.14)                    | 22 (15.71)             | 25 (17.86)      |
| Worry/anxiety                  | 0.24                   | 0.80          | 1.48 (1.35)| 58 (41.43)| 9 (6.43)                      | 21 (15.00)             | 52 (37.14)      |
| —Total cronbach                |                        |               |           | 0.79 (10.45)|                                |                        |                 |

ASTA-Br-symptom scale: Arrhythmia-Specific Questionnaire in the Tachycardia and Arrhythmia ASTA-Brazilian-Symptom scale.
may be directly related to the presence of arrhythmia. It
should be noted that when asked about these symptoms, the
participant should relate them to the arrhythmia, which
could minimise the influence of other conditions that cause
these symptoms on the participant’s response.

The majority of the respondents found the items easy to
understand, and the evaluation of usability and under-
standability only led to a few changes, suggested by the
patients.

4.1. Methodological Considerations/Limitations. The study
had some limitations. One of them was that there were few
patients diagnosed with atrial tachycardia or with ven-
tricular arrhythmias. Half of the patients were diagnosed
with the most common arrhythmia of all, AF. The majority
of respondents had low schooling and low income and
were included from two areas with different sociocultural
characteristics. In addition, due to the country’s geo-
graphic size and also because of the economic, cultural,
and social specificities of each region, perhaps this sample
is not representative of the total Brazilian population living
with tachyarrhythmia. Therefore, more studies are re-
commended that include the different regions of the
country.

5. Conclusions

The psychometric properties of the Brazilian version of the
ASTA-symptom scale evaluated in this study were satis-
factory, and the scale was proved to be a valid and reliable
tool to assess the symptom burden in patients with different
forms of tachyarrhythmia. The ASTA-BR-symptom scale
questionnaire can be an important addition to PROMs in
patients with arrhythmias and can help healthcare profes-
sionals in decision-making.

Data Availability

The data used to support the findings of this study are
available in the Research Electronic Data Capture-REDCap
platform hosted on the server of the Faculty of Medical
Sciences of Unicamp.

Conflicts of Interest

The authors declare no conflicts of interest.

Authors’ Contributions

PMSC and FPSC contributed to study conception and de-
sign, conducted the data collection, analysed the data,
interpreted the results, wrote the manuscript, and also
contributed to critical intellectual review. UW and MHBML
interpreted the results, wrote the manuscript, and also contributed to critical
intellectual review. All authors reviewed and approved the
manuscript.

Acknowledgments

The authors would like to thank the study participants and
the nursing team from the arrhythmia outpatient clinic at
the University of Campinas. This study was financed in part
by the Coordenação de Aperfeiçoamento de Pessoal de Nível
Superior (CAPES)-Brazil—Finance Code 001.

References

[1] C. Blomström-Lundqvist, M. M. Scheinman, E. M. Aliot et al.,
“ACC/AHA/ESC guidelines for the management of patients
with supraventricular arrhythmias: executive summary: a
report of the American college of cardiology/American heart
association task force on practice guidelines and the European
society of cardiology committee for practice guidelines
-writing committee to develop guidelines for the management
of patients with supraventricular arrhythmias) developed in
Collaboration with the NASPE-Heart Rhythm Society,”
Journal of the American College of Cardiology, vol. 42, no. 8,
pp. 1493–531, 2003.
[2] L. P. Magalhães, M. J. O. Figueiredo, F. D. Cintra et al., “II
diretrizes brasileiras de Fibrilação atrial,” Arquivos Brasileiros
de Cardiologia, vol. 106, no. 4, pp. 1–22, 2016.
[3] J. Brugada, D. G. Katritsis, E. Arbelo et al., “2019 ESC
guidelines for the management of patients with Supraven-
tricular Tachycardia. The task force for the management of
patients with supraventricular tachycardia of the European
society of cardiology (ESC): developed in collaboration with
the association for European paediatric and congenital car-
diolog (AEPC),” European Heart Journal, vol. 41, no. 5,
pp. 655–720, 2019.
[4] R. L. Page, J. A. Joglar, M. A. Caldwell et al., “2015 ACC/AHA/
HRS guideline for the management of adult patients with
supraventricular tachycardia: a report of the American college
of cardiology/American heart association task force on clinical
practice guidelines and the heart rhythm society,” Journal of the American College of Cardiology, vol. 67,
pp. e27–e115, 2016.
[5] U. Walfridsson and H. Walfridsson, “The impact of supra-
ventricular tachycardias on driving ability in patients referred
for radiofrequency catheter ablation,” Pacing and Clinical
Electrophysiology, vol. 28, no. 3, pp. 191–195, 2005.
[6] M. Kesek, T. Tollefsen, N. Höglund, F. Rönn, U. Näsund, and
S. M. Jensen, “U22, a protocol to quantify symptoms associ-
ated with supraventricular tachycardia,” Pacing and Clinical
Electrophysiology. Pacing Clin Electrophysiol, vol. 32, no. Suppl
1, pp. S105–S108, 2009.
[7] A. K. Gehi, S. Sears, N. Goli et al., “Psychopathology and
symptoms of atrial fibrillation: implications for therapy,”
Journal of Cardiovascular Electrophysiology, vol. 23, no. 5,
pp. 473–478, 2012.
[8] D. Smith, G. Y. H. Lip, and D. A. Lane, “Impact of symptom
control on health-related quality of life in atrial fibrillation
patients: the psychologist’s viewpoint,” Europace, vol. 12,
no. 5, pp. 608–610, 2010.
[9] K. A. Wood, C. L. Wiener, and J. Kayser-Jones, “Supraven-
tricular tachycardia and the struggle to be believed,” European
Journal of Cardiovascular Nursing, vol. 6, no. 4, pp. 293–302,
2007.
[10] P. Severino, M. V. Mariani, A. Maraone et al., “Triggers for
atrial fibrillation: the role of anxiety,” Cardiology Research and
Practice, vol. 2019, Article ID 1208505, 5 pages, 2019.
[11] M. Kesek, F. Rönn, T. Tollefsen, N. Höglund, U. Näslund, and S. M. Jensen, "Symptomatic improvement after catheter ablation of supraventricular tachycardia measured by the arrhythmia-specific questionnaire U22,” *Upsala Journal of Medical Sciences*, vol. 116, no. 1, pp. 52–59, 2011.

[12] J. García Seara, F. Guide, P. Cabanas et al., “Diferencias en la calidad de vida en pacientes con flutter auricular típico sometidos a ablación del istmo cavotricuspidio,” *Revista Española de Cardiología*, vol. 64, no. 5, pp. 401–408, 2011.

[13] Monmouth Partners, "A guide to patient reported measures—theory, landscape and uses,” 2013, http://www.monmouthpartners.com/assets/pdf/A%20Guide%20to%20Patient%20Reported%20Measures.pdf.

[14] P. Dorian, P. G. Guerra, C. R. Kerrettal.,”Validationofanew quality oflife questionnaire for atrial fibrillation,” *Circulation: Arrhythmia and Electrophysiology*, vol. 2, no. 3, pp. 319–327, 2014.

[15] J. Medin, R. Arbuckle, L. Abetz et al., “Development and validation of the AFSymQ: an atrial fibrillation-specific measure of patient-reported symptoms,” *The Patient—Patient-Centered Outcomes Research*, vol. 7, no. 3, p. 39–43, 2014.

[16] M. Härden, B. Nyström, K. Kulich et al., “Validity and reliability of a new, short symptom rating scale in patients with persistent atrial fibrillation,” *Health and Quality of Life Outcomes*, vol. 7, no. 1, p. 65, 2009.

[17] N. M. C. Alexandre and M. Z. O. Coluci, "Validade de conteúdo nos processos de construção e adaptação de instrumentos de medidas," *Ciência & Saúde Coletiva*, vol. 16, no. 7, pp. 3061–3068, 2011.

[18] M. Z. O. Coluci and N. M. C. Alexandre, "Development of a questionnaire to evaluate the usability of assessment instruments,” *Revista Enfermagem UERJ*, vol. 17, no. 3, p. 378, 2009.

[19] J. F. Hair, R. E. Anderson, R. L. Tathan et al., *Análise multivariada de dados*, Bookman, Porto Alegre, Brazil, 6 edition, 2009.

[20] E. Pfeiffer, "A short portable mental Status questionnaire for the assessment of organic brain deficit in elderly patients," *Journal of the American Geriatrics Society*, vol. 23, no. 10, pp. 433–441, 1975.

[21] P. A. Harris, R. Taylor, R. Thielke et al., “Research electronic data capture (REDCap): A metadata-driven methodology and workflow process for providing translational research informatics support,” *Journal of Biomedical Informatics*, vol. 42, no. 2, pp. 377–381, 2009.

[22] M. Pagano and K. Gauvreau, *Principios de Bioestadistica*, Thomson, São Paulo, Brazil, 2 edition, 2004.

[23] L. J. Cronbach, *Coefficient alpha and the internal structure of tests,* Psychometrika, vol. 16, no. 3, pp. 297–334, 1951.

[24] L. J. Cronbach, *Essentials of Psychological Testing*, Harper, New York, NY, USA, 2nd edition, 1960.

[25] A. D. Sperber, "Translation and validation of study instruments for cross-cultural research,” *Gastroenterology*, vol. 126, no. 1, pp. S124–S128, 2004.

[26] L. R. Oliveira and M. H. B. M. Lopes, "Validation of the Brazilian version of the Gaudenz-Fragebogen: used in the differential diagnosis of female urinary incontinence," *Escola Anna Nery Revista de Enfermagem*, vol. 20, no. 2, pp. 332–336, 2016.

[27] L. B. D. Gottems, E. M. P. Carvalho, D. Guilhem, and M. R. G. M. Pires, "Good practices in normal childbirth: reliability analysis of an instrument by Cronbach’s Alpha,” *Rev. Latino-Am. Enfermagem*, vol. 26, Article ID e3000, 2018.